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transitions from state to any other state in the data and then divides the counts by
the number of occurrences for each . The VARmethod follows Tauchen (1986) and
Terry and Knotek (2011). We compare the two methods using Monte Carlo simula-
tions by generating small samples from different data generating processes (DGPs)
and comparing the mean squared errors made by each method versus the true
transition matrix. We employ two DGPs to populate the entries of our underlying
transition probability matrices in our study: 1) A normal distribution with large
variance (DPG1), and 2) a uniform distributionwith small variance (DGP2). We then
normalize each row so they sum to 1. RESULTS: In DGP1, the VAR outperforms the
count method in small samples (N  10 or 30) and the count method marginally
outperforms the VAR method in the large sample (N  50). For DGP2, VAR outper-
forms in small samples and both methods perform similarly in the large sample.
We propose a combination of the two methods by increasing the weight on the
count method when the sample size increases relative to the size of the matrix.
CONCLUSIONS: By applying this methodology in Health Economics modeling, it
allows the researcher to utilize Markov models in situations previously infeasible
due to a paucity of data.
RESEARCH ON METHODS – Patient-Reported Outcomes Studies
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OBJECTIVES:Willingness-to-pay (WTP) analysis is a method for the monetization
of a population’s preference for a particular medication and may be determined
using a bidding game where participants are asked if they would be willing to pay
a particular amount, starting with a pre-determined value and oscillating between
a series of new WTP amounts based on their previous answer. Starting point bias
has been previously reported in the literature. The objective of the present study
was to ascertain if any bias was introduced by applying higher or lower starting
values to a bidding game. METHODS: An online survey was presented to mem-
bers of the general public in Ontario, Canada, who were presented with two
treatment delivery options (inhaler vs. injection) for a treatment of pulmonary
arterial hypertension. Participants who selected the inhaler were randomly as-
signed a starting value (CAD$1, $2 or $5) and were asked to identify their WTP in
terms of additional monthly insurance premiums. The minimum and maxi-
mum bidding game values were set at CAD$0.01 and CAD$50.00; participants
who agreed to pay CAD$50.00 were allowed to input a higher WTP explicitly, as
desired. The Kruskall-Wallis non-parametric test was applied to explore the
differences in mean WTP associated with each starting value. RESULTS: Eighty-
six participants reported a meanWTP of CAD$43.15 for the inhaler in additional
monthly insurance premium. The mean WTP were CAD$37.55, CAD$49.36 and
CAD$40.31 for participants whowere assigned to a starting point of CAD$1, $2 or
$5, respectively. No significant difference in WTP values was observed between
the groups. CONCLUSIONS:The starting value did not appear to introduce a bias in
the bidding game.
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OBJECTIVES: Different countries might have similar health preferences due to
cultural or economic factors. The aim of this study is to identify whether there are
groups of countrieswith similar health-state valuations.METHODS:A cluster anal-
ysis was performed for the 242 states of the EQ-5D valuations for 23 published
studies in 18 countries. The perfect health state was not included. The Ward algo-
rithm with the Euclidean measure and the hierarchical clustering technique were
used in order to identify the optimal number of clusters and the clusters them-
selves. The features of the resulting clusters were studied and whether there were
similarities in the countries belonging to the same cluster. The effect of the valu-
ation methodology, Visual Analogue Scale (VAS) or Time Trade Off (TTO), was also
taken into account. RESULTS: Five clusters were identified: 1) Germany-TTO, Neth-
erlands-TTO, Denmark-TTO, Argentina-TTO, Poland-TTO; 2) Belgium-VAS, Eu-
rope-VAS, New Zealand-VAS, Spain-VAS, UK-VAS, Denmark-VAS, Germany-VAS,
Slovenia-VAS; 3) Spain-TTO, UK-TTO; 4) Japan-TTO, USA-TTO, Zimbabwe-TTO,
Hispanic USA-TTO, South Korea 2009-TTO, Finland-VAS, Argentina, VAS; and 5)
South Korea 2008-TTO. Valuations are very sensitive to the preference elicitation
methodology. Hence, valuations for a country may be more similar to the valua-
tions of another country with the same methodology than to the same country
with a different methodology. Countries in the same cluster tend to have cultural
similarities (e.g. European countries with the same methodology tend to belong in
the same cluster) but a particular cluster grouped otherwise dissimilar countries
and methodologies: Japan-TTO, USA-TTO, Zimbabwe-TTO, and Argentina-VAS.
CONCLUSIONS: Health-state valuations tend to be clustered in a few groups of
countries that share cultural or economic features. These results can be used in
sensitivity analyses when performing cost-utility analysis.
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OBJECTIVES: Health economics research aims to maximise health gain within a
given budget constraint, and is predominantly achieved through themaximisation
of the quality-adjusted-life-year (QALY). Historically, the QALY assumes that indi-
viduals derive utility only from the consequences of processes and not from the
processes themselves. This assumption of narrow consequentialism suggests
health care consumers gain no benefit from the consumption of health, but that its
value is determined exclusively through health outcomes. There is growing inter-
est, however, in being able to differentiate between treatments with different pro-
cesses, such as delivery methods, in quantitative terms. This study aimed to iden-
tify and review published empirical studies which include a measure of process
utility (PU) which could be incorporated into the QALY calculation. METHODS: A
literature reviewwas performed inMedline using the search term “process utility”.
Additional searcheswere performed to identify studies not using this specific term,
for example: treatment-related attributes AND (utilities OR utility
measurement). RESULTS: Fifteen studies were identified. A variety of approaches
were used to detect and measure PU: 4 studies used standard-gamble techniques;
5 studies used time-trade-off techniques; 2 studies used conjoint analysis; 1 study
used SF-36 data; 3 studies used waiting-trade-off techniques. Eight studies evalu-
ated treatments: 5 in diabetes and the remainder in gallstone disease, HIV and pain
treatments; 6 studies evaluated testing/screening procedures and 1 study evalu-
ated preventative care. All studies identified the presence of PU. Utility decrements
ranged from 0.03-0.14 for different drug delivery methods, and 0.0005-0.12 for dif-
ferent dosing strategies. CONCLUSIONS:Although there is no universally accepted
methodology for the detection and measurement of PU, evidence to date does
support its existence. Thewide range in values and approaches suggests that stan-
dardisation of methods around the most valid approach is highly desirable. With-
out this type of consensus, comparability and validity of results will be limited.
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OBJECTIVES: To study post-transplant experience of disease and treatment among
members of the free online PatientsLikeMe® Organ Transplant Community.
METHODS: A review of the literature, existing questionnaires, and analysis of dis-
cussions between transplant recipients on the website PatientsLikeMe.com was
used to generate items for a survey in patients’ own voice. Cognitive debriefing
(n7) was used to refine the items. Including patient and treatment characteristics
the resulting online questionnaire contained 170 items informing 17 dimensions of
patient experience. We surveyed patients in the US who had received a single
organ. RESULTS: Twenty-eight percent of current, sampledmembers responded (n
 116, median completion time  22 minutes). The sample was 63% female, 72%
aged 45 or older, 77% non-Hispanic white, 41% college graduate, 62% kidney recip-
ients, 70% transplanted 2 or more years ago. There were no significant differences
between respondents and non-respondents. Over 40% of respondents rated their
health as very good or excellent; over 60% rated their life since transplant as
better than expected. On average, 7 symptoms (of 41) were reported as at least
moderately bothersome in the past 4 weeks. More symptoms correlated with
worse experience of physical, mental, emotional, and social functions and rela-
tionswith the health care team. Patientswithmore symptoms also reported poorer
immunosuppressant adherence (F4,1252.66, p  0.036). Regression analysis
showed that disease-specific impact and physical limitation were most important
to overall status. Analysis of variance showed the scales varied in sensitivity to
reported group differences in overall health, perceived adherence, and comparison
of current situationwith what the patient expected. Reliability was above .79 for 15
of 18 scales. Scale correlations were moderate. CONCLUSIONS: Using the Patient-
sLikeMe online Organ Transplantation community questions were adapted from
existing PROmeasures andnewquestionswere developed tomeasure both generic
and condition-specific experiences important to post-transplant patients.
PRM39
EXAMINATION OF STARTING POINT BIAS WITH THE BIDDING GAME:
EVIDENCE FROM A SYSTEMATIC REVIEW OF THE LITERATURE ON
WILLINGNESS-TO-PAY ANALYSES
Iskedjian M1, Navarro V2, Berbari J3, Lelorier J1
1Université de Montréal, Montréal, QC, Canada, 2PharmIdeas Europe SAS, Lyon, France,
3PharmIdeas Research and Consulting, Ottawa, ON, Canada
OBJECTIVES: Starting point (SP) bias has been reported in somewillingness-to-pay
(WTP) analyses using a bidding game (BG) approach. The objective of the present
study was to systematically reviewWTP analyses which used more than one SP to
ascertain if any bias was observed. METHODS: Using OVID MEDLINE® for 1996-
2011 and the keywords [Bidding AND (Willingness to payORWillingness-to-pay OR
WTP)], two reviewers independently identified and examinedWTP analyses which
applied more than one SP to a BG approach and which discussed any associated
bias. Additional publications were also extracted from the references of relevant
articles. Any discrepancy between the two reviewers was resolved through
consensus. RESULTS: From 51 articles yielded by the literature search, 12 met the
inclusion criteria and a further 5 were classified as secondary evidence (publica-
tions reporting on SP bias without presenting numerical data). Relevant publica-
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tionswere based in Asia (k4), North America (k3), Africa (k3) and Europe (k2).
The target population of these publications were the general public (k7), patients
(k4) or both (k1). A slight majority of the 12 primary evidence publications (k7)
and a larger majority of the 5 secondary evidence publications (k4) reported a SP
bias on the results of the BG. Various parameters such as male gender, higher
education and higher income levels were, in some instances, associated with
higherWTP amounts. Other factors analysed are the population surveyed (patients
vs. general population), and the location of the study. Association between these
factors and the occurrence of starting point bias is examined and will be reported.
CONCLUSIONS: There is evidence in the literature of a SP bias on the results of BGs,
without however a full consensus on the matter. Further research is warranted in
order to evaluate the conditions under which such bias appears.
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OBJECTIVES: Patient reported outcomes (PROs) have become an important compo-
nent of many clinical studies. The use of ePRO as a data collection method can
alleviate the potential burden experienced by patients and/or sites. The purpose of
this survey studywas to capture current PROdata collection trends and summarize
these findings side-by-sidewith results fromaprevious PROdata collection survey.
METHODS: Industry professionals were invited to complete a web-based survey
fielded in late 2011 and early 2012. This survey included questions on professional
demographics, experience using PROs (and ePROs) by study type and experience
with ePRO technologies. Responses were analyzed descriptively. RESULTS: To
date, 54 industry professionals completed the 2011-2012 survey. Fifty nine percent
of respondents were from pharmaceutical companies, biotech (26%), medical de-
vice (9%), and other (6%).While 49% of respondents in the 2010 survey had previous
PRO study experience, 60% of respondents in the current survey had previous PRO
experience. The proportion of respondents with prior ePRO experience, however,
was similar across the two surveys (51% in 2010 and 54% in 2011-2012). Hand-held
device (tablet, PDA) was the most common ePRO technology (71% in 2011, 64% in
2010), followed by interactive voice response (47% in 2011, 60% in 2010), and inter-
active web-response (29% in 2011, 51% in 2010). Among those with prior ePRO
exposure in 2011 and 2010, respectively, 59% and 86% strongly agreed/agreed they
would use ePRO in future studies. Among thosewho never used ePROs, 58% in 2011
and 50% in 2010 indicated they would likely use ePROs in future studies.
CONCLUSIONS: Results from this survey suggest that ePRO use continues to gain
moderate acceptance among industry professionals. These findings, however,
were based on a limited sample size. Future surveys should be administered to
allow future trends in ePRO use to be observed over time.
PRM41
TRANSLATION AND CULTURAL ADAPTATION OF THE LANGUAGE
DEVELOPMENT SURVEY
Griffin A1, Wild D1, Rescorla L2, Sunderaju R3
1Oxford Outcomes, Oxford, Oxfordshire, UK, 2Bryn Mawr College, Bryn Mawr, PA, USA,
3University of Vermont, Burlington, VA, USA
OBJECTIVES: The Language Development Survey (LDS) assesses children’s word
combinations and vocabulary and provides an accurate picture of a child’s devel-
oping language when completed by a parent or guardian. The LDS contains a list of
310 basic words. The person completing the questionnaire is asked to circle those
words their child says spontaneously. Translations already existed in over ten
languages. Twelve further languages were translated, including eight Indic lan-
guages. A direct translation of some source words was not possible as some items
are unknown in the target country, e.g. pretzel, spaghetti, Sesame St. Therefore, it
was necessary to find a conceptually equivalent source word. METHODS: Two
approaches were adopted: An initial translatability assessment was carried out to
identify problematic words. Equivalent source words were suggested. Further
problematic words were identified during the translation and cognitive-debriefing
process. Alternatives were suggested either during the translation stages or by the
parent/guardian during the cognitive debriefing interview. Final wording was
agreed on through discussion with the lead in-country translator and instrument
developers. RESULTS: A number of cultural adaptations were made. For all Indian
languages, ‘cracker’ was translated as ‘papadom’ (a thin, crisp Indian cracker) and
‘pizza’ as translated as ‘dosa’ (a type of Indian pancake). This was decided before
the initial translation step. ‘Sesame St.’ was replaced with ‘Tom and Jerry’. In
French ‘saucisse’ was suggested as an alternative for ‘hot dog’ during cognitive
debriefing.CONCLUSIONS:When translating a patient-reported outcome (PRO) the
aim is to produce a translation that is conceptually equivalent to the source text. In
some cases, cultural adaptation is essential. Translation of the LDS is an excellent
example of this methodology and the translations are now available for use in
multi-national studies.
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OBJECTIVES: This session intends to identify patients’ preferences for receiving
reminders when participating in clinical trials. Results of a survey on patient ex-
periences will be reported. Recommendations for developing reminder strategies
will be provided with the intention of enhancing the patient’s experience and
compliance. METHODS: An internet survey was administered to patients (in De-
cember 2010) who participated in at least one clinical trial with patient diaries in
the past two years. The survey focused on patients’ perceived experiences and
preferences with patient diaries/ePRO, and how patient diary methods could be
improved. This session will focus on the questions relating to patient reminders–
specifically relating to preferences for how reminderswere sent/received, activities
for which reminders were found most useful, frequency of reminders, etc.
RESULTS: Reminder methods patients preferred most were email and text mes-
sages. Two areas patients preferred to be reminded about were any action required
of them as part of their clinical trial participation and when they were required to
record an electronic-diary entry. When patients were asked about how often they
wanted to receive reminders, the most frequent responses included whenever
there was new information related to their trial participation and once per day.
Patients also provided suggestions for reminders in future trials. CONCLUSIONS:
The results focus onwhat patients are telling industry what they do/do not want in
terms of reminders; these perspectives should be accounted for to enhance the
patient journey and compliance. If industry implements the reminder strategy
wrong (for instance, annoying patients by reminding them too frequently), that
may actually impact compliance negatively. Remind patients when necessary/not
too often. Remind patients in ways they will be able to best receive/notice them.
Appropriate use of reminders drives compliance and incorporating patient prefer-
ences will not only improve compliances rates, but will also enhance the patient’s
experience.
RESEARCH ON METHODS – Statistical Methods
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OBJECTIVES: Accurately estimating the upper bounds of confidence intervals for
rare events such as hospitalization or death is an important activity in safety stud-
ies and outcomes research. Confidence intervals, however, for rare events are sub-
ject to considerable variation based upon the overall sample size and total number
of observed events. This has led to a challenging convention that a minimum of 2
or 3 events are needed for computing meaningful confidence intervals. The objec-
tive of this study was to quantify the variation of the upper bound of confidence
intervals for a binomial proportion in the setting of rare events. METHODS: Clop-
per-Pearson confidence intervals were constructed for sample sizes ranging from
50 to 1000, and numbers of events from 0 to 5. The robustness of the confidence
interval was evaluated by calculating additional confidence intervals assuming: 1)
one more observed event than in the original sample and, 2) that the proportion of
events is equal to the upper bound of the confidence interval for the original
sample. RESULTS: With sample sizes of 50, 100, 200, 500 and 1000, the upper
bounds of the confidence intervals were 13.71%, 7.04%, 3.57%, 1.44% and 0.72%,
respectively, with 2 observed events in the original sample; 16.55%, 8.52%, 4.32%,
1.74% and 0.87%, respectively, (3 observed events); and, 26.40%, 13.94%, 7.16%,
2.91% and 1.47%, respectively, when the proportion of events was equal to the
upper bound of the confidence interval for the original sample with 2 events. Sim-
ilar trends were seen when using other numbers of observed events.
CONCLUSIONS: The upper bounds of confidence intervals for rare events vary
greatly with sample sizes and the numbers of events observed when the sample
size is small. A minimum of 500 subjects is optimal for constructing confidence
intervals for rare events, even if 2 events or less are observed.
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OBJECTIVES:Todevelop and test a three-way propensity scorematching algorithm
to provide pseudo-randomization of subjects into three groups to allow for com-
parable groups in a retrospective study. METHODS: Logistic regression using the
generalized multinomial logit linking function was used to calculate estimates of
the propensity score: the probability of having received three putatively inter-
changeable drugs from demographic (Race, Gender, Age) and comorbidities (Charl-
son Comorbidities Index) in a large, retrospective database. The most costly drug
was used as the reference group, and the probability of each treatment group
having received the reference drug was retained as the propensity score. In the
initial analysis 23,912, 4,789, and 4,318 individualswere available in the three treat-
ment regimens. Random subsets of 1/4 and 1/10 the original sample were con-
structed for the purpose assessing multi-group propensity score matching (PSM)
effectiveness in constructing comparable groups via pseudo-randomization with
varying starting sample sizes. PSM was conducted using calipers ranging from 8
digits to one digit of propensity score. Assessment of among-group differences
before and after PSM were conducted using Chi-square tests for categorical vari-
ables and GLM analysis, with difference scores and their confidence intervals for
continuous variables. RESULTS: For all sample sizes, prior to propensity score
matching, significant differences existed among the three treatment regimens for
all variables: gender, race, age and comorbidities. Following PSM there were 3381
matched triplets in the full sample. There were no significant differences among
groups for gender, age or comorbidities; there were significant but tiny differences
that remained for racial representation. In the smaller samples, 966 and 416
matched triplets were retained. There were no significant differences on any
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